Article on the results of phase II study with MesoPher in resected pancreatic cancer published in MedNous, June 2022 - Amphera

Article on the results of phase II study with MesoPher in resected pancreatic cancer published in MedNous, June 2022

Previous Amphera’s MesoPher cell therapy demonstrates favourable safety and promising survival in a phase II clinical trial in resected pancreatic cancer

Next Last patient completed follow-up period in Phase II/III study of Amphera’s MesoPher cell therapy in mesothelioma